Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

References

• International Diabetes Federation IDF Diabetes Atlas 6th ed Brussels International Diabetes Federation 2013
   Google Scholar
• American Diabetes Association Standards of medical care in diabetes – 2013 Diabetes Care 2013 36 Suppl 1 S11 S66 23264422
   PubMed Web of Science ®Google Scholar
• Saaddine JB Engelgau MM Beckles GL Gregg EW Thompson TJ Narayan KM A diabetes report card for the United States: quality of care in the 1990s Ann Intern Med 2002 136 8 565 574 11955024
   PubMed Web of Science ®Google Scholar
• Drucker DJ Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes Expert Opin Investig Drugs 2003 12 1 87 100
   PubMed Web of Science ®Google Scholar
• Holst JJ Vilsbøll T Deacon CF The incretin system and its role in type 2 diabetes mellitus Mol Cell Endocrinol 2009 297 1–2 127 136 18786605
   PubMed Web of Science ®Google Scholar
• Pontikis C Yavropoulou MP Toulis KA The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study J Womens Health (Larchmt) 2011 20 6 971 976 21671782
   PubMed Web of Science ®Google Scholar
• Pospisilik JA Martin J Doty T Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats Diabetes 2003 52 3 741 750 12606516
   PubMed Web of Science ®Google Scholar
• Kim HJ Kwak WY Min JP Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes Bioorg Med Chem Lett 2011 21 12 3809 3812 21570283
   PubMed Web of Science ®Google Scholar
• Cho JM Jang HW Cheon H A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis Diabetes Res Clin Pract 2011 91 1 72 79 21093089
   PubMed Web of Science ®Google Scholar
• Kim MK Chae YN Kim HD DA-1229, a novel and potent DPP4 inhibitor, improves insulin resistance and delays the onset of diabetes Life Sci 2012 90 1–2 21 29 22056373
   PubMed Web of Science ®Google Scholar
• Kim TE Lim KS Park MK Evaluation of the pharmacokinetics, food effect, pharmacodynamics, and tolerability of DA-1229, a dipeptidyl peptidase IV inhibitor, in healthy volunteers: first-in-human study Clin Ther 2012 34 9 1986 1998 22943970
   PubMed Web of Science ®Google Scholar
• Drucker DJ Sherman SI Gorelick FS Bergenstal RM Sherwin RS Buse JB Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits Diabetes Care 2010 33 2 428 433 20103558
   PubMed Web of Science ®Google Scholar
• Kazafeos K Incretin effect: GLP-1, GIP, DPP4 Diabetes Res Clin Pract 2011 93 Suppl 1 S32 S36 21864749
   PubMed Web of Science ®Google Scholar
• Scheen AJ Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes Eur J Intern Med 2012 23 2 126 131 22284241
   PubMed Web of Science ®Google Scholar
• Davidson JA Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors Mayo Clin Proc 2010 85 Suppl 12 S27 S37 21106865
   PubMedGoogle Scholar
• Gerich J DPP-4 inhibitors: what may be the clinical differentiators? Diabetes Res Clin Pract 2010 90 2 131 140 20708812
   PubMed Web of Science ®Google Scholar
• Scheen AJ Pharmacokinetics of dipeptidyl peptidase-4 inhibitors Diabetes Obes Metab 2010 12 8 648 658 20590741
   PubMed Web of Science ®Google Scholar
• Scheen AJ A review of gliptins in 2011 Expert Opin Pharmacother 2012 13 1 81 99 22149369
   PubMed Web of Science ®Google Scholar
• Baetta R Corsini A Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences Drugs 2011 71 11 1441 1467 21812507
   PubMed Web of Science ®Google Scholar
• He YL Clinical pharmacokinetics and pharmacodynamics of vildagliptin Clin Pharmacokinet 2012 51 3 147 162 22339447
   PubMed Web of Science ®Google Scholar
• Li H Yang L Tou CK Patel CG Zhao J Pharmacokinetic study of saxagliptin in healthy Chinese subjects Clin Drug Investig 2012 32 7 465 473
   Web of Science ®Google Scholar
• Gutniak M GLP-1 (7–36)amide [GLIP-glucagon like insulinotropic peptide] as a potential treatment for NIDDM Journ Annu Diabetol Hotel Dieu 1998 157 171 French 9773617
   PubMedGoogle Scholar
• Flint A Raben A Ersbøll AK Holst JJ Astrup A The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity Int J Obes Relat Metab Disord 2001 25 6 781 792 11439290
   PubMed Web of Science ®Google Scholar
• Knauf C Cani PD Perrin C Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage J Clin Invest 2005 115 12 3554 3563 16322793
   PubMed Web of Science ®Google Scholar
• Lindgren O Mari A Deacon CF Differential islet and incretin hormone responses in morning versus afternoon after standardized meal in healthy men J Clin Endocrinol Metab 2009 94 8 2887 2892 19435824
   PubMed Web of Science ®Google Scholar
• Melani F Verrillo A Marasco M Rivellese A Osorio J Bertolini MG Diurnal variation in blood sugar and serum insulin in response to glucose and/or glucagon in healthy subjects Horm Metab Res 1976 8 2 85 88 944163
   PubMed Web of Science ®Google Scholar
• Lee A Ader M Bray GA Bergman RN Diurnal variation in glucose tolerance. Cyclic suppression of insulin action and insulin secretion in normal-weight, but not obese, subjects Diabetes 1992 41 6 750 759 1587401
   PubMed Web of Science ®Google Scholar
• Van Cauter E Shapiro ET Tillil H Polonsky KS Circadian modulation of glucose and insulin responses to meals: relationship to cortisol rhythm Am J Physiol 1992 262 4 Pt 1 E467 E475 1566835
   PubMed Web of Science ®Google Scholar
• Saad A Dalla Man C Nandy DK Diurnal pattern to insulin secretion and insulin action in healthy individuals Diabetes 2012 61 11 2691 2700 22751690
   PubMed Web of Science ®Google Scholar